What’S New In Musk-Mg?

Myasthenia gravis (MG) is an autoimmune disease, caused by autoantibodies against proteins of the neuromuscular junction, leading to impaired neuromuscular transmission and fatigable muscle weakness. Around 85% of patients have Abs against the acetylcholine receptor (AChR). Among AChR-negative cases, Abs against the muscle-specific kinase (anti-MuSK) are detected in up to 40%. Over the last decades, a significant increase in elderly patients with AChR-MG has been reported. Similar demographic changes, although less pronounced, have also been observed in the MuSK-MG population.

Recent advances in the understanding of MuSK-MG have suggested a potential role for IgA autoantibodies in disease pathogenesis and clinical course. Furthermore, the possible association between MuSK-MG and malignancies remains an area of ongoing investigation and scientific interest. A growing number of target therapies for MG are becoming available. Awareness of these emerging data may have relevant implications for clinical practice, contributing to improved diagnostic strategies, patient stratification, and personalized therapeutic approaches.

Continuous scientific updating is therefore essential for neurologists and healthcare professionals involved in the management of patients with MG. The aim of this webinar is to provide an updated overview of recent advances in MuSK-MG, with particular focus on demographics, clinical characteristics and pathogenesis. Through expert presentations and discussion, participants will have the opportunity to critically review the latest evidence and its potential impact on daily clinical practice.